Abilify Injectable - Search News

Abilify Asimtufii Approved for Schizophrenia, Bipolar I Disorder

Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...

Business Wire

Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month, Ready-to-Use, Long-Acting Injectable is as Well-Tolerated, and Provides Similar Plasma Levels as ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...

Monthly Prescribing Reference

Aripiprazole 2-Month Under Review for Schizophrenia, Bipolar I Disorder

The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot. The Food and Drug Administration (FDA) ...

Healio

FDA approves long-acting injectable for schizophrenia, bipolar I disorder

Please provide your email address to receive an email when new articles are posted on . The FDA approved a new drug application for a treatment for schizophrenia or bipolar I disorder. The injectable ...

STAT

New long-acting injectable helps manage schizophrenia or bipolar I symptoms for two-months

According to the National Institute on Minority Health and Health Disparities (NIMHD), less than half of all Americans who have a mental disorder get proper treatment, and less than 10% of patients ...

EurekAlert!

ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old

Otsuka Pharmaceutical Co., Ltd., and Bristol-Myers Squibb Company announced today that the US FDA approved the supplemental New Drug Application for ABILIFY for the acute treatment of manic and mixed ...

Business Wire

ABILIFY® (aripiprazole) Supplemental New Drug Application For Pediatric Patients With Schizophrenia Accepted For Priority Review By The U.S. Food And Drug Administration

ABILIFY Injection, an injectable form of ABILIFY for intramuscular use, provides healthcare professionals with the first ready-to-use single dose vial (9.75 mg/1.3 mL) of an atypical antipsychotic to ...

Prevention

Understanding Treatment Options This World Mental Health Day

ABILIFY MAINTENA® (aripiprazole). Please see IMPORTANT SAFETY INFORMATION, including BOXED WARNING for INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS, for ABILIFY ASIMTUFII ...

Pharmabiz

US FDA approves Otsuka & Lundbeck's Abilify Asimtufii, the first, two-month, LAI to treat schizophrenia or maintenance monotherapy treatment of bipolar I disorder in adults

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Abilify ...